Transparency: EMA rejects Abbvie copyright claims, mulls InterMune patent ploy
This article was originally published in Scrip
In trying to prevent the European Medicines Agency from releasing clinical trial data on its blockbuster product Humira (adalimumab), Abbvie is claiming not only that the documents in question are commercially confidential, but that releasing them would be a breach of copyright law.
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.